Show simple item record

dc.contributor.authorYerlikaya, Azmi
dc.contributor.authorAltıkat, Sayit
dc.contributor.authorIrmak, Reyhan
dc.contributor.authorCavga, Fatma Zehra
dc.contributor.authorKocacan, Sultan Aysun
dc.contributor.authorBoyacı, İhsan
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T20:01:50Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T20:01:50Z
dc.date.issued2013en_US
dc.identifier.citationYerlikaya, A., Altıkat, S., Irmak, R., Cavga, F. Z., Kocacan, S. A. ve Boyacı, İ. (2013). Effect of bortezomib in combination with cisplatin and 5-fluorouracil on 4T1 breast cancer cells. Molecular Medicine Reports, 8(1), 277-281. https://dx.doi.org/10.3892/mmr.2013.1466en_US
dc.identifier.issn1791-2997
dc.identifier.issn1791-3004
dc.identifier.urihttps://dx.doi.org/10.3892/mmr.2013.1466
dc.identifier.urihttps://hdl.handle.net/20.500.12511/3459
dc.descriptionWOS: 000321079300046en_US
dc.descriptionPubMed ID: 23660746en_US
dc.description.abstractBortezomib is a highly selective and reversible inhibitor of the 26S proteasome. It has been approved for the treatment of patients with relapsed and refractory multiple myeloma. A number of studies have been conducted to evaluate. the activity and safety of bortezomib either alone or in combination with several cytotoxic agents and radiation. In the current study, the efficacy of bortezomib alone or in combination with cisplatin and 5-fluorouracil was evaluated in 4T1 breast cancer cells, a highly metastatic murine cancer cell line. Using MTT assay, IC50 values of cisplatin and 5-fluorouracil were determined to be 14.2 and 8.9 mu M for cisplatin and 5-fluorouracil, respectively. The effects of different concentrations of cisplatin and 5-fluorouracil in combination with two different concentrations of bortezomib were examined in the 4T1 cells. Statistically significant differences were found when 1 or 5 mu M cisplatin was combined with 10 or 50 nM bortezomib. Similarly, 1 mu M 5-fluorouracil or 5 mu M 5-fluorouracil in combination with 10 nM bortezomib caused significant cell death as compared to treatment with single agents. However, 1 or 5 mu M 5-fluorouracil did not potentiate the effects of higher concentrations of bortezomib (50 nM). The effect of the combination of cisplatin, 5-fluorouracil and bortezomib was determined by soft agar assay. It was confirmed that a combination of cisplatin and bortezomib was more effective than each drug as a monotherapy. Therefore, the combination of cisplatin and bortezomib should be tested further in clinical settings.en_US
dc.language.isoengen_US
dc.publisherSpandidos Publicationsen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBortezomiben_US
dc.subjectCanceren_US
dc.subjectCisplatinen_US
dc.subject5-Fluorouracilen_US
dc.titleEffect of bortezomib in combination with cisplatin and 5-fluorouracil on 4T1 breast cancer cellsen_US
dc.typearticleen_US
dc.relation.ispartofMolecular Medicine Reportsen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.authorid0000-0001-7369-0426en_US
dc.identifier.volume8en_US
dc.identifier.issue1en_US
dc.identifier.startpage277en_US
dc.identifier.endpage281en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.3892/mmr.2013.1466en_US
dc.identifier.wosqualityQ3en_US
dc.identifier.scopusqualityQ3en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record